Navigation Links
Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Date:1/11/2010

SAN DIEGO, Jan. 11 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for 2:00 p.m. PST on Thursday, January 14, at the Westin St. Francis in San Francisco, Calif. The J.P. Morgan Healthcare Conference is one of the largest and most informative healthcare investment symposiums in the industry. Over 300 public and private companies are expected to present at the conference.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
2. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
3. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
4. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
5. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Poniard Pharmaceuticals Announces $6.5 Million Financing
8. Titan Pharmaceuticals to Receive $3 Million Loan
9. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
10. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
11. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... December 23, 2014 The report ... its definition, classification, application and industry overview. This ... product cost structure. Production is separated by regions, ... raw materials, equipment, downstream client survey, marketing channels, ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Groton , Connecticut MORRISVILLE, N.C., May ... of APIs, intermediates and Drug Products to the pharmaceutical industry, ... announce the recent award by Pfizer Inc. as the 2008 ... Groton, Connecticut R&D center on May 1, 2009. The award ...
... Blinatumomab in NHL and ALL Highlighted at the ... Combination Data in Breast Cancer to Be Presented ... MeetingBETHESDA, Md., May 20 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ...
... WOODMERE, N.Y., May 19 In an eleventh-hour attempt ... QGLY ) has issued a press release claiming that ... a key staff member of a subsidiary of Quigley, and ... who have offered their own slate of Quigley,s Board of ...
Cached Biology Technology:Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Proline-serine-threonine phosphatase-interacting protein 2...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: